Cefamandole nafate
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Cefamandole nafate is a second generation cephalosporin indicated in the prevention of infections during surgery.
- Generic Name
- Cefamandole nafate
- DrugBank Accession Number
- DB14725
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 490.51
Monoisotopic: 490.072924672 - Chemical Formula
- C19H18N6O6S2
- Synonyms
- O-formylcefamandole
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prophylaxis of Susceptible bacterial infections •••••••••••• ••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefamandole nafate. Acenocoumarol The risk or severity of bleeding can be increased when Cefamandole nafate is combined with Acenocoumarol. Alteplase The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefamandole nafate. Ambroxol The risk or severity of methemoglobinemia can be increased when Cefamandole nafate is combined with Ambroxol. Ancrod The therapeutic efficacy of Ancrod can be decreased when used in combination with Cefamandole nafate. - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Cefamandole nafate sodium 8HDO7941DO 42540-40-9 ICZOIXFFVKYXOM-YCLOEFEOSA-M - Active Moieties
Name Kind UNII CAS InChI Key Cefamandole prodrug 5CKP8C2LLI 34444-01-4 OLVCFLKTBJRLHI-AXAPSJFSSA-N - International/Other Brands
- Kefadol (Lilly) / Kefandol (Lilly) / Mandokef (Lilly) / Mandol (Lilly)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Mandol Add-vantage Inj 1gm/vial Powder, for solution 1 g / vial Intravenous Eli Lilly & Co. Ltd. 1989-12-31 1998-08-04 Canada Mandol Inj 1gm/amp Powder, for solution 1 g / amp Intramuscular; Intravenous Eli Lilly & Co. Ltd. 1978-12-31 2000-10-02 Canada Mandol Inj 2gm/amp Powder, for solution 2 g / amp Intravenous Eli Lilly & Co. Ltd. 1978-12-31 2000-08-03 Canada
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 57268-80-1
- InChI Key
- RRJHESVQVSRQEX-SUYBPPKGSA-N
- InChI
- InChI=1S/C19H18N6O6S2/c1-24-19(21-22-23-24)33-8-11-7-32-17-12(16(28)25(17)13(11)18(29)30)20-15(27)14(31-9-26)10-5-3-2-4-6-10/h2-6,9,12,14,17H,7-8H2,1H3,(H,20,27)(H,29,30)/t12-,14-,17-/m1/s1
- IUPAC Name
- (6R,7R)-7-[(2R)-2-(formyloxy)-2-phenylacetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- SMILES
- [H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](OC=O)C1=CC=CC=C1)C(O)=O
References
- General References
- BPOM Product Information: Cefamandole nafate injection [Link]
- External Links
- ChemSpider
- 4447585
- 20473
- ChEBI
- 53654
- ChEMBL
- CHEMBL1201218
- ZINC
- ZINC000003830397
- Wikipedia
- Cefamandole
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 0 Terminated Treatment Osteomyelitis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Parenteral 1 G Injection, powder, for solution Parenteral Powder, for solution Intravenous 1 g / vial Powder, for solution Intramuscular; Intravenous 1 g / amp Powder, for solution Intravenous 2 g / amp - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.227 mg/mL ALOGPS logP 0.61 ALOGPS logP 0.42 Chemaxon logS -3.3 ALOGPS pKa (Strongest Acidic) 3.1 Chemaxon pKa (Strongest Basic) -1.7 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 156.61 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 131.31 m3·mol-1 Chemaxon Polarizability 45.27 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0005-0000900000-b624996562f8c9775fa5 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-01ti-0025900000-17a7fb272f095b47a1a4 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-006t-0323900000-79266a91d969274e4f01 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-00dr-9100000000-e3edc6013c5fb86309fd Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-052f-9400100000-4cf48213cba11024447d Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-02wc-3955400000-a33746483ac6cb0575ff Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 221.9828044 predictedDarkChem Lite v0.1.0 [M+H]+ 222.6989044 predictedDarkChem Lite v0.1.0 [M+Na]+ 222.5335044 predictedDarkChem Lite v0.1.0
Drug created at December 14, 2018 17:21 / Updated at August 17, 2021 04:17